BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 32289272)

  • 1. Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance.
    Kilgour E; Rothwell DG; Brady G; Dive C
    Cancer Cell; 2020 Apr; 37(4):485-495. PubMed ID: 32289272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine.
    Rossi G; Ignatiadis M
    Cancer Res; 2019 Jun; 79(11):2798-2804. PubMed ID: 31109952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Fast and Furious Liquid Biopsy Assay to Monitor Targeted Therapy Resistance.
    Nicolazzo C; Gazzaniga P
    Methods Mol Biol; 2022; 2535():93-104. PubMed ID: 35867225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of liquid biopsies in colorectal cancer.
    Wills B; Gorse E; Lee V
    Curr Probl Cancer; 2018 Nov; 42(6):593-600. PubMed ID: 30268335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid Biopsy: From Basic Research to Clinical Practice.
    Macías M; Alegre E; Díaz-Lagares A; Patiño A; Pérez-Gracia JL; Sanmamed M; López-López R; Varo N; González A
    Adv Clin Chem; 2018; 83():73-119. PubMed ID: 29304904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid Biopsies for Neuroendocrine Tumors: Circulating Tumor Cells, DNA, and MicroRNAs.
    Rizzo FM; Meyer T
    Endocrinol Metab Clin North Am; 2018 Sep; 47(3):471-483. PubMed ID: 30098711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How liquid biopsies can change clinical practice in oncology.
    Siravegna G; Mussolin B; Venesio T; Marsoni S; Seoane J; Dive C; Papadopoulos N; Kopetz S; Corcoran RB; Siu LL; Bardelli A
    Ann Oncol; 2019 Oct; 30(10):1580-1590. PubMed ID: 31373349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA.
    Junqueira-Neto S; Batista IA; Costa JL; Melo SA
    Acta Cytol; 2019; 63(6):479-488. PubMed ID: 30783027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumour Cells in Predictive Molecular Pathology: Focus on Drug-Sensitive Assays and 3D Culture.
    Pallante P; Pisapia P; Bellevicine C; Malapelle U; Troncone G
    Acta Cytol; 2019; 63(3):171-181. PubMed ID: 30759433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid Biopsy in Primary Brain Tumors: Looking for Stardust!
    Fontanilles M; Duran-Peña A; Idbaih A
    Curr Neurol Neurosci Rep; 2018 Mar; 18(3):13. PubMed ID: 29520561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies.
    Russo M; Bardelli A
    Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 28003276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies.
    Esposito A; Criscitiello C; Locatelli M; Milano M; Curigliano G
    Pharmacol Ther; 2016 Jan; 157():120-4. PubMed ID: 26615782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
    Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
    Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers.
    Addanki S; Meas S; Sarli VN; Singh B; Lucci A
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.
    Carpinetti P; Donnard E; Bettoni F; Asprino P; Koyama F; Rozanski A; Sabbaga J; Habr-Gama A; Parmigiani RB; Galante PA; Perez RO; Camargo AA
    Oncotarget; 2015 Nov; 6(35):38360-71. PubMed ID: 26451609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Tumor DNA: A Step into the Future of Cancer Management.
    Fernandes Marques J; Pereira Reis J; Fernandes G; Hespanhol V; Machado JC; Costa JL
    Acta Cytol; 2019; 63(6):456-465. PubMed ID: 30852572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic Melanoma: Liquid Biopsy as a New Precision Medicine Approach.
    Ricciardi E; Giordani E; Ziccheddu G; Falcone I; Giacomini P; Fanciulli M; Russillo M; Cerro M; Ciliberto G; Morrone A; Guerrisi A; Valenti F
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
    Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
    Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential of liquid biopsy in the management of cancer patients.
    Markou A; Tzanikou E; Lianidou E
    Semin Cancer Biol; 2022 Sep; 84():69-79. PubMed ID: 35331850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
    Fici P
    Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.